Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,365,000 ordinary shares of 25 pence each.
- Purchase Price: 1,402.76 pence per share.
- Treasury Holdings: 208,769,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,779,184,424 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 2,365,000 shares on October 31, 2006, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying the 2,365,000 shares by the 1,402.76 pence price.
- Confirm the updated share count of 5,779,184,424 shares in issue for valuation models.
- Note that the company holds over 208 million shares in Treasury, which may impact future capital allocation decisions.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) and return on equity (ROE).